These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 31479024)

  • 1. Visual Prognosis in the Better-seeing Eyes of Patients with Unilateral Polypoidal Choroidal Vasculopathy.
    Kim JH; Kim JW; Kim CG; Lee DW
    Optom Vis Sci; 2019 Sep; 96(9):686-694. PubMed ID: 31479024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.
    Saito M; Kano M; Itagaki K; Ise S; Imaizumi K; Sekiryu T
    Jpn J Ophthalmol; 2016 Jan; 60(1):35-41. PubMed ID: 26350229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy with polyps resembling grape clusters.
    Lee JH; Lee WK
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):645-51. PubMed ID: 26138657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ANGIOGRAPHIC FINDINGS OF RANIBIZUMAB-RESISTANT POLYPOIDAL CHOROIDAL VASCULOPATHY AFTER SWITCHING TO A TREAT-AND-EXTEND REGIMEN WITH INTRAVITREAL AFLIBERCEPT.
    Azuma K; Obata R; Nomura Y; Tan X; Takahashi H; Yanagi Y
    Retina; 2016 Nov; 36(11):2158-2165. PubMed ID: 27258669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ONE-YEAR RESULTS OF INTRAVITREAL AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Hara C; Sawa M; Sayanagi K; Nishida K
    Retina; 2016 Jan; 36(1):37-45. PubMed ID: 26383709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Komuku Y; Iwahashi C; Gomi F
    Jpn J Ophthalmol; 2020 May; 64(3):265-270. PubMed ID: 32206935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: As Needed Versus Fixed Interval Dosing.
    Inoue M; Yamane S; Taoka R; Arakawa A; Kadonosono K
    Retina; 2016 Aug; 36(8):1527-34. PubMed ID: 26710307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy.
    Hosokawa M; Shiraga F; Yamashita A; Shiragami C; Ono A; Shirakata Y; Kimura S; Shiode Y; Kawata T; Hosogi M; Fujiwara A; Morizane Y
    Br J Ophthalmol; 2015 Aug; 99(8):1087-91. PubMed ID: 25712826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal Anti-vascular Endothelial Growth Factor for Newly Diagnosed Symptomatic Polypoidal Choroidal Vasculopathy with Extrafoveal Polyps.
    Kim JH; Lee DW; Choi SC; Kim JW; Lee TG; Kim CG; Cho HJ
    Korean J Ophthalmol; 2015 Dec; 29(6):404-10. PubMed ID: 26635457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term efficacy of intravitreal aflibercept for patients with treatment-naïve polypoidal choroidal vasculopathy.
    Ijiri S; Sugiyama K
    Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):351-7. PubMed ID: 25023147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CLINICAL OUTCOME OF POLYPOIDAL CHOROIDAL VASCULOPATHY/ANEURYSMAL TYPE 1 NEOVASCULARIZATION ACCORDING TO CHOROIDAL VASCULAR MORPHOLOGY.
    Baek J; Lee JH; Lee K; Chung BJ; Lee WK
    Retina; 2020 Nov; 40(11):2166-2174. PubMed ID: 31834135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Sakurada Y; Sugiyama A; Tanabe N; Kikushima W; Kume A; Iijima H
    Retina; 2017 Oct; 37(10):1866-1872. PubMed ID: 28002268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct Responsiveness to Intravitreal Ranibizumab Therapy in Polypoidal Choroidal Vasculopathy With Single or Multiple Polyps.
    Suzuki M; Nagai N; Shinoda H; Uchida A; Kurihara T; Tomita Y; Kamoshita M; Iyama C; Tsubota K; Ozawa Y
    Am J Ophthalmol; 2016 Jun; 166():52-59. PubMed ID: 27017997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polypoidal choroidal vasculopathy in patients aged less than 50 years: characteristics and 6-month treatment outcome.
    Chang YS; Kim JH; Kim JW; Lee TG; Kim CG; Cho SW
    Graefes Arch Clin Exp Ophthalmol; 2016 Jun; 254(6):1083-9. PubMed ID: 26384678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy.
    Cho HJ; Kim KM; Kim HS; Han JI; Kim CG; Lee TG; Kim JW
    Am J Ophthalmol; 2016 May; 165():1-6. PubMed ID: 26921806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.
    Kang HM; Koh HJ; Lee CS; Lee SC
    Am J Ophthalmol; 2014 Mar; 157(3):598-606.e1. PubMed ID: 24269378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between the arm-to-choroidal circulation time and clinical profile in patients with polypoidal choroidal vasculopathy.
    Mukai R; Itagaki K; Honjyo J; Tanaka K; Norikawa K; Sekiryu T
    Jpn J Ophthalmol; 2024 May; 68(3):211-215. PubMed ID: 38609716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy.
    Yamamoto A; Okada AA; Kano M; Koizumi H; Saito M; Maruko I; Sekiryu T; Iida T
    Ophthalmology; 2015 Sep; 122(9):1866-72. PubMed ID: 26088619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-year visual outcomes of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.
    Sakai T; Okano K; Kohno H; Tsuneoka H
    Acta Ophthalmol; 2016 Dec; 94(8):e765-e771. PubMed ID: 27237048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
    Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Nishida K
    Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.